Study Name:
Open-label Multi-Cohort 1b/2: Safety, Efficacy, and Optimal Dose Telisotuzumab Adizutecan Combination PD-1 Immune Checkpoint Inhibitor in Advanced/Metastatic NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The study will address the hypothesis that telisotuzumab adizutecan in combination with a PD-1 immune check point inhibitor (budigalimab or pembrolizumab) can be safely administered and telisotuzumab adizutecan in combination with pembrolizumab will provide a favorable risk/benefit profile compared to the SOC control (pembrolizumab and platinum doublet) in subjects with locally advanced/metastatic NSq NSCLC who have no prior systemic therapy for advanced disease and who are EGFR WT and have no known other actionable genomic alterations.
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
CA
Lead Institution:
Private Research Clinic
Funding Source:
AbbVie Inc.
Sponsors:
AbbVie Inc.
Contact:
Paula Chacon
Contact Phone: 805-4653-574 Ext 162
Contact Email: [email protected]
ClinicalTrails.gov Identifier:
M24-536
